Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.
- Journal
- PubMed
In The Last Decade
doi.org/w38765079 →Countries where authors are citing Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.
This map shows the geographic impact of Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. more than expected).
Fields of papers citing Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.
This network shows the impact of Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition..
About Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.
This paper, published in 1996, received 536 indexed citations . Written by D. Ferry, Adam J. de Smith, D. Fyfe, David A. Anderson, J Baker and Rachel Kerr covering the research area of Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. It is primarily cited by scholars working on Molecular Biology (243 citations), Biochemistry (158 citations) and Oncology (87 citations). Published in PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/w38765079.